The global market for Squamous Non-Small Cell Lung Cancer Therapeutics was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Squamous Non-Small Cell Lung Cancer Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Squamous Non-Small Cell Lung Cancer Therapeutics.

The Squamous Non-Small Cell Lung Cancer Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Squamous Non-Small Cell Lung Cancer Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Squamous Non-Small Cell Lung Cancer Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Squamous Non-Small Cell Lung Cancer Therapeutics Market Report

Report Metric	Details
Report Name	Squamous Non-Small Cell Lung Cancer Therapeutics Market
CAGR	5%
Segment by Type	BMS-906024 Buparlisib Hydrochloride FP-1039 Ipilimumab JNJ-42756493 Lenvatinib Others
Segment by Application	Research Center Hospital Clinic
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Ascenta Therapeutics, Inc., AstraZeneca Plc, AVEO Pharmaceuticals, Inc., Bayer AG, BIND Therapeutics, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Five Prime Therapeutics, Inc., Genentech, Inc., Incyte Corporation, Johnson & Johnson, MacroGenics, Inc., Novartis AG, Oncogenex Pharmaceuticals, Inc., PsiOxus Therapeutics Limited
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Squamous Non-Small Cell Lung Cancer Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Squamous Non-Small Cell Lung Cancer Therapeutics Market report?

Ans: The main players in the Squamous Non-Small Cell Lung Cancer Therapeutics Market are Ascenta Therapeutics, Inc., AstraZeneca Plc, AVEO Pharmaceuticals, Inc., Bayer AG, BIND Therapeutics, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Five Prime Therapeutics, Inc., Genentech, Inc., Incyte Corporation, Johnson & Johnson, MacroGenics, Inc., Novartis AG, Oncogenex Pharmaceuticals, Inc., PsiOxus Therapeutics Limited

What are the Application segmentation covered in the Squamous Non-Small Cell Lung Cancer Therapeutics Market report?

Ans: The Applications covered in the Squamous Non-Small Cell Lung Cancer Therapeutics Market report are Research Center, Hospital, Clinic

What are the Type segmentation covered in the Squamous Non-Small Cell Lung Cancer Therapeutics Market report?

Ans: The Types covered in the Squamous Non-Small Cell Lung Cancer Therapeutics Market report are BMS-906024, Buparlisib Hydrochloride, FP-1039, Ipilimumab, JNJ-42756493, Lenvatinib, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 BMS-906024

1.2.3 Buparlisib Hydrochloride

1.2.4 FP-1039

1.2.5 Ipilimumab

1.2.6 JNJ-42756493

1.2.7 Lenvatinib

1.2.8 Others

1.3 Market by Application

1.3.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Research Center

1.3.3 Hospital

1.3.4 Clinic

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Perspective (2020-2031)

2.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Growth Trends by Region

2.2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Squamous Non-Small Cell Lung Cancer Therapeutics Historic Market Size by Region (2020-2025)

2.2.3 Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Region (2026-2031)

2.3 Squamous Non-Small Cell Lung Cancer Therapeutics Market Dynamics

2.3.1 Squamous Non-Small Cell Lung Cancer Therapeutics Industry Trends

2.3.2 Squamous Non-Small Cell Lung Cancer Therapeutics Market Drivers

2.3.3 Squamous Non-Small Cell Lung Cancer Therapeutics Market Challenges

2.3.4 Squamous Non-Small Cell Lung Cancer Therapeutics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Squamous Non-Small Cell Lung Cancer Therapeutics Players by Revenue

3.1.1 Global Top Squamous Non-Small Cell Lung Cancer Therapeutics Players by Revenue (2020-2025)

3.1.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Players (2020-2025)

3.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Squamous Non-Small Cell Lung Cancer Therapeutics Revenue

3.4 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Concentration Ratio

3.4.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in 2024

3.5 Global Key Players of Squamous Non-Small Cell Lung Cancer Therapeutics Head office and Area Served

3.6 Global Key Players of Squamous Non-Small Cell Lung Cancer Therapeutics, Product and Application

3.7 Global Key Players of Squamous Non-Small Cell Lung Cancer Therapeutics, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Squamous Non-Small Cell Lung Cancer Therapeutics Breakdown Data by Type

4.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Historic Market Size by Type (2020-2025)

4.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Type (2026-2031)

5 Squamous Non-Small Cell Lung Cancer Therapeutics Breakdown Data by Application

5.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Historic Market Size by Application (2020-2025)

5.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2020-2031)

6.2 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2020-2025)

6.4 North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2020-2031)

7.2 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2020-2025)

7.4 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2020-2031)

8.2 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (2020-2025)

8.4 Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2020-2031)

9.2 Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2020-2025)

9.4 Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (2020-2031)

10.2 Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2020-2025)

10.4 Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Ascenta Therapeutics, Inc.

11.1.1 Ascenta Therapeutics, Inc. Company Details

11.1.2 Ascenta Therapeutics, Inc. Business Overview

11.1.3 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction

11.1.4 Ascenta Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

11.1.5 Ascenta Therapeutics, Inc. Recent Development

11.2 AstraZeneca Plc

11.2.1 AstraZeneca Plc Company Details

11.2.2 AstraZeneca Plc Business Overview

11.2.3 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Introduction

11.2.4 AstraZeneca Plc Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

11.2.5 AstraZeneca Plc Recent Development

11.3 AVEO Pharmaceuticals, Inc.

11.3.1 AVEO Pharmaceuticals, Inc. Company Details

11.3.2 AVEO Pharmaceuticals, Inc. Business Overview

11.3.3 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction

11.3.4 AVEO Pharmaceuticals, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

11.3.5 AVEO Pharmaceuticals, Inc. Recent Development

11.4 Bayer AG

11.4.1 Bayer AG Company Details

11.4.2 Bayer AG Business Overview

11.4.3 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Introduction

11.4.4 Bayer AG Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

11.4.5 Bayer AG Recent Development

11.5 BIND Therapeutics, Inc.

11.5.1 BIND Therapeutics, Inc. Company Details

11.5.2 BIND Therapeutics, Inc. Business Overview

11.5.3 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction

11.5.4 BIND Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

11.5.5 BIND Therapeutics, Inc. Recent Development

11.6 Boehringer Ingelheim GmbH

11.6.1 Boehringer Ingelheim GmbH Company Details

11.6.2 Boehringer Ingelheim GmbH Business Overview

11.6.3 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Introduction

11.6.4 Boehringer Ingelheim GmbH Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

11.6.5 Boehringer Ingelheim GmbH Recent Development

11.7 Bristol-Myers Squibb Company

11.7.1 Bristol-Myers Squibb Company Company Details

11.7.2 Bristol-Myers Squibb Company Business Overview

11.7.3 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Introduction

11.7.4 Bristol-Myers Squibb Company Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

11.7.5 Bristol-Myers Squibb Company Recent Development

11.8 Eli Lilly and Company

11.8.1 Eli Lilly and Company Company Details

11.8.2 Eli Lilly and Company Business Overview

11.8.3 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Introduction

11.8.4 Eli Lilly and Company Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

11.8.5 Eli Lilly and Company Recent Development

11.9 F. Hoffmann-La Roche Ltd.

11.9.1 F. Hoffmann-La Roche Ltd. Company Details

11.9.2 F. Hoffmann-La Roche Ltd. Business Overview

11.9.3 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction

11.9.4 F. Hoffmann-La Roche Ltd. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

11.9.5 F. Hoffmann-La Roche Ltd. Recent Development

11.10 Five Prime Therapeutics, Inc.

11.10.1 Five Prime Therapeutics, Inc. Company Details

11.10.2 Five Prime Therapeutics, Inc. Business Overview

11.10.3 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction

11.10.4 Five Prime Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

11.10.5 Five Prime Therapeutics, Inc. Recent Development

11.11 Genentech, Inc.

11.11.1 Genentech, Inc. Company Details

11.11.2 Genentech, Inc. Business Overview

11.11.3 Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction

11.11.4 Genentech, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

11.11.5 Genentech, Inc. Recent Development

11.12 Incyte Corporation

11.12.1 Incyte Corporation Company Details

11.12.2 Incyte Corporation Business Overview

11.12.3 Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Introduction

11.12.4 Incyte Corporation Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

11.12.5 Incyte Corporation Recent Development

11.13 Johnson & Johnson

11.13.1 Johnson & Johnson Company Details

11.13.2 Johnson & Johnson Business Overview

11.13.3 Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Introduction

11.13.4 Johnson & Johnson Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

11.13.5 Johnson & Johnson Recent Development

11.14 MacroGenics, Inc.

11.14.1 MacroGenics, Inc. Company Details

11.14.2 MacroGenics, Inc. Business Overview

11.14.3 MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction

11.14.4 MacroGenics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

11.14.5 MacroGenics, Inc. Recent Development

11.15 Novartis AG

11.15.1 Novartis AG Company Details

11.15.2 Novartis AG Business Overview

11.15.3 Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Introduction

11.15.4 Novartis AG Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

11.15.5 Novartis AG Recent Development

11.16 Oncogenex Pharmaceuticals, Inc.

11.16.1 Oncogenex Pharmaceuticals, Inc. Company Details

11.16.2 Oncogenex Pharmaceuticals, Inc. Business Overview

11.16.3 Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Introduction

11.16.4 Oncogenex Pharmaceuticals, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

11.16.5 Oncogenex Pharmaceuticals, Inc. Recent Development

11.17 PsiOxus Therapeutics Limited

11.17.1 PsiOxus Therapeutics Limited Company Details

11.17.2 PsiOxus Therapeutics Limited Business Overview

11.17.3 PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Introduction

11.17.4 PsiOxus Therapeutics Limited Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

11.17.5 PsiOxus Therapeutics Limited Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Ascenta Therapeutics, Inc.

Astrazeneca plc

AVEO Pharmaceuticals Inc

Bayer

BIND Therapeutics, Inc.

Boehringer Ingelheim GmbH

Bristol Myers Squibb Company

Eli Lilly and Company

F Hoffmann La Roche Ltd

Five Prime Therapeutics Inc

Oncogenex Pharmaceuticals Inc

PsiOxus Therapeutics Limited

List of Tables

Table 1. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of BMS-906024

Table 3. Key Players of Buparlisib Hydrochloride

Table 4. Key Players of FP-1039

Table 5. Key Players of Ipilimumab

Table 6. Key Players of JNJ-42756493

Table 7. Key Players of Lenvatinib

Table 8. Key Players of Others

Table 9. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 10. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 11. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (2020-2025) & (US$ Million)

Table 12. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Region (2020-2025)

Table 13. Global Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 14. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Region (2026-2031)

Table 15. Squamous Non-Small Cell Lung Cancer Therapeutics Market Trends

Table 16. Squamous Non-Small Cell Lung Cancer Therapeutics Market Drivers

Table 17. Squamous Non-Small Cell Lung Cancer Therapeutics Market Challenges

Table 18. Squamous Non-Small Cell Lung Cancer Therapeutics Market Restraints

Table 19. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Players (2020-2025) & (US$ Million)

Table 20. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Players (2020-2025)

Table 21. Global Top Squamous Non-Small Cell Lung Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics as of 2024)

Table 22. Ranking of Global Top Squamous Non-Small Cell Lung Cancer Therapeutics Companies by Revenue (US$ Million) in 2024

Table 23. Global 5 Largest Players Market Share by Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (CR5 and HHI) & (2020-2025)

Table 24. Global Key Players of Squamous Non-Small Cell Lung Cancer Therapeutics, Headquarters and Area Served

Table 25. Global Key Players of Squamous Non-Small Cell Lung Cancer Therapeutics, Product and Application

Table 26. Global Key Players of Squamous Non-Small Cell Lung Cancer Therapeutics, Date of Enter into This Industry

Table 27. Mergers & Acquisitions, Expansion Plans

Table 28. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Type (2020-2025) & (US$ Million)

Table 29. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Type (2020-2025)

Table 30. Global Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 31. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Type (2026-2031)

Table 32. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2020-2025) & (US$ Million)

Table 33. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Application (2020-2025)

Table 34. Global Squamous Non-Small Cell Lung Cancer Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 35. Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Application (2026-2031)

Table 36. North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 38. North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 39. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 40. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 41. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 42. Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 43. Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (2020-2025) & (US$ Million)

Table 44. Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Region (2026-2031) & (US$ Million)

Table 45. Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 47. Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 48. Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 49. Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 50. Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 51. Ascenta Therapeutics, Inc. Company Details

Table 52. Ascenta Therapeutics, Inc. Business Overview

Table 53. Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product

Table 54. Ascenta Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)

Table 55. Ascenta Therapeutics, Inc. Recent Development

Table 56. AstraZeneca Plc Company Details

Table 57. AstraZeneca Plc Business Overview

Table 58. AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Product

Table 59. AstraZeneca Plc Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)

Table 60. AstraZeneca Plc Recent Development

Table 61. AVEO Pharmaceuticals, Inc. Company Details

Table 62. AVEO Pharmaceuticals, Inc. Business Overview

Table 63. AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product

Table 64. AVEO Pharmaceuticals, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)

Table 65. AVEO Pharmaceuticals, Inc. Recent Development

Table 66. Bayer AG Company Details

Table 67. Bayer AG Business Overview

Table 68. Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Product

Table 69. Bayer AG Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)

Table 70. Bayer AG Recent Development

Table 71. BIND Therapeutics, Inc. Company Details

Table 72. BIND Therapeutics, Inc. Business Overview

Table 73. BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product

Table 74. BIND Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)

Table 75. BIND Therapeutics, Inc. Recent Development

Table 76. Boehringer Ingelheim GmbH Company Details

Table 77. Boehringer Ingelheim GmbH Business Overview

Table 78. Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Product

Table 79. Boehringer Ingelheim GmbH Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)

Table 80. Boehringer Ingelheim GmbH Recent Development

Table 81. Bristol-Myers Squibb Company Company Details

Table 82. Bristol-Myers Squibb Company Business Overview

Table 83. Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Product

Table 84. Bristol-Myers Squibb Company Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)

Table 85. Bristol-Myers Squibb Company Recent Development

Table 86. Eli Lilly and Company Company Details

Table 87. Eli Lilly and Company Business Overview

Table 88. Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Product

Table 89. Eli Lilly and Company Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)

Table 90. Eli Lilly and Company Recent Development

Table 91. F. Hoffmann-La Roche Ltd. Company Details

Table 92. F. Hoffmann-La Roche Ltd. Business Overview

Table 93. F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Product

Table 94. F. Hoffmann-La Roche Ltd. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)

Table 95. F. Hoffmann-La Roche Ltd. Recent Development

Table 96. Five Prime Therapeutics, Inc. Company Details

Table 97. Five Prime Therapeutics, Inc. Business Overview

Table 98. Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product

Table 99. Five Prime Therapeutics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)

Table 100. Five Prime Therapeutics, Inc. Recent Development

Table 101. Genentech, Inc. Company Details

Table 102. Genentech, Inc. Business Overview

Table 103. Genentech, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product

Table 104. Genentech, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)

Table 105. Genentech, Inc. Recent Development

Table 106. Incyte Corporation Company Details

Table 107. Incyte Corporation Business Overview

Table 108. Incyte Corporation Squamous Non-Small Cell Lung Cancer Therapeutics Product

Table 109. Incyte Corporation Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)

Table 110. Incyte Corporation Recent Development

Table 111. Johnson & Johnson Company Details

Table 112. Johnson & Johnson Business Overview

Table 113. Johnson & Johnson Squamous Non-Small Cell Lung Cancer Therapeutics Product

Table 114. Johnson & Johnson Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)

Table 115. Johnson & Johnson Recent Development

Table 116. MacroGenics, Inc. Company Details

Table 117. MacroGenics, Inc. Business Overview

Table 118. MacroGenics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product

Table 119. MacroGenics, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)

Table 120. MacroGenics, Inc. Recent Development

Table 121. Novartis AG Company Details

Table 122. Novartis AG Business Overview

Table 123. Novartis AG Squamous Non-Small Cell Lung Cancer Therapeutics Product

Table 124. Novartis AG Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)

Table 125. Novartis AG Recent Development

Table 126. Oncogenex Pharmaceuticals, Inc. Company Details

Table 127. Oncogenex Pharmaceuticals, Inc. Business Overview

Table 128. Oncogenex Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Product

Table 129. Oncogenex Pharmaceuticals, Inc. Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)

Table 130. Oncogenex Pharmaceuticals, Inc. Recent Development

Table 131. PsiOxus Therapeutics Limited Company Details

Table 132. PsiOxus Therapeutics Limited Business Overview

Table 133. PsiOxus Therapeutics Limited Squamous Non-Small Cell Lung Cancer Therapeutics Product

Table 134. PsiOxus Therapeutics Limited Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025) & (US$ Million)

Table 135. PsiOxus Therapeutics Limited Recent Development

Table 136. Research Programs/Design for This Report

Table 137. Key Data Information from Secondary Sources

Table 138. Key Data Information from Primary Sources

Table 139. Authors List of This Report

List of Figures

Figure 1. Squamous Non-Small Cell Lung Cancer Therapeutics Picture

Figure 2. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Type: 2024 VS 2031

Figure 4. BMS-906024 Features

Figure 5. Buparlisib Hydrochloride Features

Figure 6. FP-1039 Features

Figure 7. Ipilimumab Features

Figure 8. JNJ-42756493 Features

Figure 9. Lenvatinib Features

Figure 10. Others Features

Figure 11. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size by Application (2020-2031) & (US$ Million)

Figure 12. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Application: 2024 VS 2031

Figure 13. Research Center Case Studies

Figure 14. Hospital Case Studies

Figure 15. Clinic Case Studies

Figure 16. Squamous Non-Small Cell Lung Cancer Therapeutics Report Years Considered

Figure 17. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 18. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 19. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Region: 2024 VS 2031

Figure 20. Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Players in 2024

Figure 21. Global Top Squamous Non-Small Cell Lung Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Squamous Non-Small Cell Lung Cancer Therapeutics as of 2024)

Figure 22. The Top 10 and 5 Players Market Share by Squamous Non-Small Cell Lung Cancer Therapeutics Revenue in 2024

Figure 23. North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. North America Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Country (2020-2031)

Figure 25. United States Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Canada Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Europe Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Country (2020-2031)

Figure 29. Germany Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. France Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. U.K. Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Italy Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Russia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Nordic Countries Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Asia-Pacific Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Region (2020-2031)

Figure 37. China Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Japan Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. South Korea Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. India Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Australia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Latin America Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Country (2020-2031)

Figure 45. Mexico Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Brazil Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Middle East & Africa Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Country (2020-2031)

Figure 49. Turkey Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. Saudi Arabia Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 51. UAE Squamous Non-Small Cell Lung Cancer Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 52. Ascenta Therapeutics, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

Figure 53. AstraZeneca Plc Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

Figure 54. AVEO Pharmaceuticals, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

Figure 55. Bayer AG Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

Figure 56. BIND Therapeutics, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

Figure 57. Boehringer Ingelheim GmbH Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

Figure 58. Bristol-Myers Squibb Company Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

Figure 59. Eli Lilly and Company Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

Figure 60. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

Figure 61. Five Prime Therapeutics, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

Figure 62. Genentech, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

Figure 63. Incyte Corporation Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

Figure 64. Johnson & Johnson Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

Figure 65. MacroGenics, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

Figure 66. Novartis AG Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

Figure 67. Oncogenex Pharmaceuticals, Inc. Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

Figure 68. PsiOxus Therapeutics Limited Revenue Growth Rate in Squamous Non-Small Cell Lung Cancer Therapeutics Business (2020-2025)

Figure 69. Bottom-up and Top-down Approaches for This Report

Figure 70. Data Triangulation

Figure 71. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Precision Cancer Imaging System Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-23Z10214

Thu Feb 20 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Cryosurgical Equipment for Cancer Treatment Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-39B12765

Thu Feb 20 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Brachytherapy Accessories Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-24Q18678

Tue Feb 18 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Gynecological Cancer Diagnostics Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-30P10282

Mon Feb 17 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions